(Total Views: 389)
Posted On: 10/18/2019 12:14:41 PM
Post# of 153969
What you refer to as Matinas' (MTNB) "fish oil" product is MAT 9001.
In an early stage, very small, clinical trial MAT 9001 handily bested Amarin's Vascepa in lowering triglycerides.
This could be very significant, as Amarin recently completed the Phase 3 REDUCE-IT trial for Vascepa which showed a 25% reduction in cardiovascular events, and is likely to soon get a label expansion for this additional indication.
Matinas has scheduled a second, much larger, head-to-head trial against Vascepa, with results to be announced, I believe, in 2020. If these results again confirm the superiority of MAT 9001 over Vascepa, the SP of MTNB should take off.
Matinas recently received a $25M non-dilutive investment that the company says will fund its operations through mid-2021.
In addition, the NIH is running, and paying for, clinical trials of one of Matinas's lead drugs.
Matinas also has agreements with two big pharmas, including VIIV, to run clinical trials to determine whether the company's lipid nano crystal delivery platform, aka encochleation, can make highly toxic IV drugs, such as amphotericin b, safe to take orally, while retaining efficacy.
Results of some early trials appear to be very promising.
All of this, and much more, is explained on the company's website, which posts a number of presentations of its CEO, Jerry Jabbour.
I have found that when Jabbour makes a promise, or a projection as to what he expects to happen in the future for the company, these generally turn out to be true and accurate.
I am an early stage investor in Matinas, and think it will ultimately be worth many times its current SP.
LM
In an early stage, very small, clinical trial MAT 9001 handily bested Amarin's Vascepa in lowering triglycerides.
This could be very significant, as Amarin recently completed the Phase 3 REDUCE-IT trial for Vascepa which showed a 25% reduction in cardiovascular events, and is likely to soon get a label expansion for this additional indication.
Matinas has scheduled a second, much larger, head-to-head trial against Vascepa, with results to be announced, I believe, in 2020. If these results again confirm the superiority of MAT 9001 over Vascepa, the SP of MTNB should take off.
Matinas recently received a $25M non-dilutive investment that the company says will fund its operations through mid-2021.
In addition, the NIH is running, and paying for, clinical trials of one of Matinas's lead drugs.
Matinas also has agreements with two big pharmas, including VIIV, to run clinical trials to determine whether the company's lipid nano crystal delivery platform, aka encochleation, can make highly toxic IV drugs, such as amphotericin b, safe to take orally, while retaining efficacy.
Results of some early trials appear to be very promising.
All of this, and much more, is explained on the company's website, which posts a number of presentations of its CEO, Jerry Jabbour.
I have found that when Jabbour makes a promise, or a projection as to what he expects to happen in the future for the company, these generally turn out to be true and accurate.
I am an early stage investor in Matinas, and think it will ultimately be worth many times its current SP.
LM
(0)
(0)
The Lawman
style="color:red">The Lawman"color:red">The Lawman:red">The LawmanThe Lawmanspan>Lawmanawmanimg]
